BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2507341)

  • 1. Prevention or moderation of some ultrastructural changes in the RPE and retina of galactosemic rats by aldose reductase inhibition.
    Vinores SA; Campochiaro PA
    Exp Eye Res; 1989 Sep; 49(3):495-510. PubMed ID: 2507341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats.
    Vinores SA; McGehee R; Lee A; Gadegbeku C; Campochiaro PA
    J Histochem Cytochem; 1990 Sep; 38(9):1341-52. PubMed ID: 2117624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Permeability changes in blood-retinal barrier of galactosemic rats are prevented by aldose reductase inhibitors.
    Lightman S; Rechthand E; Terubayashi H; Palestine A; Rapoport S; Kador P
    Diabetes; 1987 Nov; 36(11):1271-5. PubMed ID: 3117606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening--prevention by an aldose reductase inhibitor.
    Das A; Frank RN; Zhang NL; Samadani E
    Exp Eye Res; 1990 Mar; 50(3):269-80. PubMed ID: 2108050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The polyol pathway in retinal microangiopathy.
    Robison WG; Kinoshita JH; Kador PF
    Drugs; 1986; 32 Suppl 2():19-22. PubMed ID: 3098542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of aldose reductase inhibition on nerve sorbitol and myoinositol concentrations in diabetic and galactosemic rats.
    Yue DK; Hanwell MA; Satchell PM; Handelsman DJ; Turtle JR
    Metabolism; 1984 Dec; 33(12):1119-22. PubMed ID: 6438438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galactose-induced retinal microangiopathy in rats.
    Kern TS; Engerman RL
    Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):490-6. PubMed ID: 7843917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinal polyol and myo-inositol in galactosemic dogs given an aldose-reductase inhibitor.
    Kern TS; Engerman RL
    Invest Ophthalmol Vis Sci; 1991 Dec; 32(13):3175-7. PubMed ID: 1748548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.
    Datiles M; Fukui H; Kuwabara T; Kinoshita JH
    Invest Ophthalmol Vis Sci; 1982 Feb; 22(2):174-9. PubMed ID: 6799419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with aldose reductase inhibitor or with myo-inositol arrests deterioration of the electroretinogram of diabetic rats.
    MacGregor LC; Matschinsky FM
    J Clin Invest; 1985 Aug; 76(2):887-9. PubMed ID: 3928685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of an aldose reductase inhibitor, SNK-860, on the histopathological changes of retinal tissues in a streptozotocin-induced diabetic rat model.
    Akita M; Mizuno K; Matsubara A; Nakano K; Kurono M
    Acta Med Okayama; 1993 Oct; 47(5):299-304. PubMed ID: 8273453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor.
    Robison WG; Kador PF; Kinoshita JH
    Science; 1983 Sep; 221(4616):1177-9. PubMed ID: 6612330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldose reductase activity and basement membrane thickening.
    Frank RN
    Metabolism; 1986 Apr; 35(4 Suppl 1):35-40. PubMed ID: 3083207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats.
    Tilton RG; Pugliese G; LaRose LS; Faller AM; Chang K; Province MA; Williamson JR
    J Diabet Complications; 1991; 5(4):230-7. PubMed ID: 1779018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electron microscopic immunocytochemical evidence for the mechanism of blood-retinal barrier breakdown in galactosemic rats and its association with aldose reductase expression and inhibition.
    Vinores SA; Van Niel E; Swerdloff JL; Campochiaro PA
    Exp Eye Res; 1993 Dec; 57(6):723-35. PubMed ID: 8150024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of aldose reductase in diabetic corneal epitheliopathy. Second report: The corneal epithelium of galactosemic rats].
    Takahashi Y; Akagi Y; Akimune M; Tamura K; Itoi M
    Nippon Ganka Gakkai Zasshi; 1986 Feb; 90(2):336-40. PubMed ID: 3085442
    [No Abstract]   [Full Text] [Related]  

  • 17. Capillary basement membrane in retina, kidney, and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition.
    Engerman RL; Kern TS; Garment MB
    J Diabetes Complications; 1993; 7(4):241-5. PubMed ID: 8219367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of aldose reductase inhibition on the retina and health indices of streptozotocin-diabetic rats.
    Kozak WM; Marker NA; Elmer KK
    Doc Ophthalmol; 1986; 64(4):355-77. PubMed ID: 2958262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
    Engerman RL; Kern TS
    Diabetes; 1993 Jun; 42(6):820-5. PubMed ID: 8495805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs.
    Datiles MB; Kador PF; Kashima K; Kinoshita JH; Sinha A
    Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2201-4. PubMed ID: 2122961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.